RU2485113C2 - Ингибиторы цитокинов - Google Patents

Ингибиторы цитокинов Download PDF

Info

Publication number
RU2485113C2
RU2485113C2 RU2010122333/04A RU2010122333A RU2485113C2 RU 2485113 C2 RU2485113 C2 RU 2485113C2 RU 2010122333/04 A RU2010122333/04 A RU 2010122333/04A RU 2010122333 A RU2010122333 A RU 2010122333A RU 2485113 C2 RU2485113 C2 RU 2485113C2
Authority
RU
Russia
Prior art keywords
imidazo
phenyl
pyridazin
oxadiazol
methyl
Prior art date
Application number
RU2010122333/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010122333A (ru
Inventor
Вэй ДЭН
Вэй-Го СУ
Юй ЦАЙ
Джефф ДУАНЬ
Original Assignee
Хатчисон Медифарма Энтерпрайзис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хатчисон Медифарма Энтерпрайзис filed Critical Хатчисон Медифарма Энтерпрайзис
Publication of RU2010122333A publication Critical patent/RU2010122333A/ru
Application granted granted Critical
Publication of RU2485113C2 publication Critical patent/RU2485113C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2010122333/04A 2007-11-02 2008-10-31 Ингибиторы цитокинов RU2485113C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/934,154 2007-11-02
US11/934,154 US7868001B2 (en) 2007-11-02 2007-11-02 Cytokine inhibitors
PCT/US2008/082027 WO2009059162A1 (en) 2007-11-02 2008-10-31 Cytokine inhibitors

Publications (2)

Publication Number Publication Date
RU2010122333A RU2010122333A (ru) 2011-12-10
RU2485113C2 true RU2485113C2 (ru) 2013-06-20

Family

ID=40588767

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010122333/04A RU2485113C2 (ru) 2007-11-02 2008-10-31 Ингибиторы цитокинов

Country Status (11)

Country Link
US (1) US7868001B2 (enExample)
EP (1) EP2214669B1 (enExample)
JP (1) JP5733982B2 (enExample)
KR (1) KR20100101581A (enExample)
AU (1) AU2008318491B2 (enExample)
CA (1) CA2704431A1 (enExample)
MX (1) MX2010004774A (enExample)
MY (1) MY153065A (enExample)
RU (1) RU2485113C2 (enExample)
TW (1) TWI419692B (enExample)
WO (1) WO2009059162A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH066861Y2 (ja) 1991-02-19 1994-02-23 太陽電子株式会社 パチンコ式組合せゲーム機
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011137587A1 (en) * 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
EA201650031A1 (ru) 2014-05-15 2017-06-30 Итеос Терапьютик Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
KR102302109B1 (ko) * 2014-07-24 2021-09-14 삼성디스플레이 주식회사 유기 화합물 및 이를 포함하는 유기 발광 장치
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
BR112017019699A2 (pt) 2015-03-17 2018-09-04 Pfizer Inc. derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso
US10544095B2 (en) 2015-08-10 2020-01-28 Pfizer Inc. 3-indol substituted derivatives, pharmaceutical compositions and methods for use
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018118781A1 (en) * 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018348350B2 (en) 2017-10-11 2024-05-02 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2020004531A (es) 2017-11-03 2020-08-03 Aurigene Discovery Tech Ltd Inhibidores dobles de tim-3 y las vias de pd-1.
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Pd—1/pd—l1抑制劑之鹽
US20220267270A1 (en) * 2019-08-30 2022-08-25 University Of South Florida Sting modulators, compositions, and methods of use
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
GB202019622D0 (en) * 2020-12-11 2021-01-27 Adorx Therapeutics Ltd Antagonist compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2001128066A (ru) * 1999-03-17 2003-07-10 Астразенека Аб Производные амида
RU2220142C2 (ru) * 1999-01-19 2003-12-27 Берингер Ингельхайм Фармасьютиклз, Инк. Ароматические гетероциклические соединения как противовоспалительные средства
US20040127521A1 (en) * 2002-12-18 2004-07-01 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20060084650A1 (en) * 2004-10-15 2006-04-20 Qing Dong Kinase inhibitors
US20070049620A1 (en) * 2003-06-11 2007-03-01 Sankyo Company, Limited Cyclic tertiary amine compound
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745237B2 (enExample) * 1974-03-27 1982-09-27
GB1442707A (en) * 1973-07-07 1976-07-14 Yoshitomi Pharmaceutical Substituted phenylalkanoic acids and their derivatives and pharma ceutical compositions thereof
DE3446812A1 (de) 1984-12-21 1986-06-26 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JPH07291976A (ja) * 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔2,1−b〕チアゾール誘導体
JP3477238B2 (ja) * 1994-04-27 2003-12-10 株式会社大塚製薬工場 イミダゾ〔1,2−a〕ピリジン誘導体
DE60010448T2 (de) * 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2450555A1 (en) * 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
EP1426050A4 (en) * 2001-08-23 2005-05-25 Takeda Pharmaceutical JNK INHIBITORS
ATE511858T1 (de) * 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
CA2551867C (en) 2003-12-31 2010-08-17 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
JP2008504294A (ja) * 2004-06-25 2008-02-14 アムジエン・インコーポレーテツド サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
US20060064650A1 (en) * 2004-09-20 2006-03-23 International Business Machines Corporation Method, system, and computer program product for type-based table navigation
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US20090163476A1 (en) * 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
AU2006311786A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
CA2707360A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CA2695251C (en) * 2007-08-14 2016-06-21 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
EP2083009A1 (de) * 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
PA8854101A1 (es) * 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2220142C2 (ru) * 1999-01-19 2003-12-27 Берингер Ингельхайм Фармасьютиклз, Инк. Ароматические гетероциклические соединения как противовоспалительные средства
RU2001128066A (ru) * 1999-03-17 2003-07-10 Астразенека Аб Производные амида
US20040127521A1 (en) * 2002-12-18 2004-07-01 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20070049620A1 (en) * 2003-06-11 2007-03-01 Sankyo Company, Limited Cyclic tertiary amine compound
US20060084650A1 (en) * 2004-10-15 2006-04-20 Qing Dong Kinase inhibitors
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
WO2007034278A3 (en) * 2005-09-19 2007-05-18 Pfizer Prod Inc Fused imidazole derivatives as c3a receptor antagonists

Also Published As

Publication number Publication date
KR20100101581A (ko) 2010-09-17
EP2214669B1 (en) 2015-04-01
WO2009059162A1 (en) 2009-05-07
CA2704431A1 (en) 2009-05-07
MX2010004774A (es) 2010-07-02
EP2214669A1 (en) 2010-08-11
RU2010122333A (ru) 2011-12-10
JP2011502996A (ja) 2011-01-27
MY153065A (en) 2014-12-31
TWI419692B (zh) 2013-12-21
US20090118292A1 (en) 2009-05-07
AU2008318491A1 (en) 2009-05-07
JP5733982B2 (ja) 2015-06-10
US7868001B2 (en) 2011-01-11
EP2214669A4 (en) 2011-11-09
AU2008318491B2 (en) 2013-09-19
TW201002327A (en) 2010-01-16

Similar Documents

Publication Publication Date Title
EP2214669B1 (en) Cytokine inhibitors
JP6704421B2 (ja) Dnaアルキル化剤
JP6431770B2 (ja) Mekインヒビターとしてのヘテロシクリル化合物
EP0225013B1 (en) Heterocyclic compounds and their preparation and use
US5811428A (en) Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
JP5091944B2 (ja) イミダゾ[1,2−b]ピリダジン、その調製方法及びGABA受容体リガンドとしてのその使用
JPH11512399A (ja) ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
SK4882003A3 (en) Nitroso diphenylamine derivative, process for the preparation thereof, its use and pharmaceutical composition containing same
WO2003070725A2 (en) Process for preparing indolinone derivatives
CN105358546A (zh) 用作激酶抑制剂的经取代的四氢咔唑及咔唑甲酰胺化合物
US5847136A (en) Deazapurine derivatives; a new class of CRF1 specific ligands
JP4917428B2 (ja) 2−置換フェニル−5,7−ジアルキル−3,7−ジヒドロピロロ[2,3−d]ピリミジン−4−オン誘導体、その製法およびその医薬用途
JPH0412270B2 (enExample)
US4780539A (en) 3-substituted-4,5-dihydro-5-oxo imidazoquinazolines, their preparation, and their use in treating benzodiazepin receptor-related ailments
CA2532437C (en) N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto
JP2010540423A (ja) ピロロピリミジン化合物類
CN102617578A (zh) 一种咪唑衍生物及其医药用途
US5804685A (en) Deazapurine derivatives: a new class of CRF1 specific ligands
KR100508156B1 (ko) 신규한 캐테콜 히드라자이드 유도체
KR20010005492A (ko) 아릴아미노 트리아졸로피리딘의 제조 방법
JP2016030747A (ja) オキサジン誘導体及びその医薬用途

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151101